banner
PDE inhibitor, Vardenafil, Purity ≥98%
Inquiry

Cat. No.: X24-08-YM489

PDE inhibitor, Vardenafil, Purity ≥98%

Synonym: 224785-90-4; Vardenafil hydrochloride trihydrate; Levitra; Vivanza; 2-[2-Ethoxy-5-(4-ethylpiperazin-1-yl)sulfonylphenyl]-5-methyl-7-propyl-3H-imidazo[5,1-f][1,2,4]triazin-4-one

  • CAS Number: 224785-90-4
  • Compound CID: 135400189
img
Product Size
25 mg; 50 mg; 100 mg; 500 mg
Price
Datasheet
MSDS
Properties
Description
Vardenafil is an effective cell metabolism inhibitor, that has the ability to prevent the pathway of metabolism by inhibiting PDE. It targets the PDE1, PDE3, PDE4, and PDE5.
Molecular Weight
579.1
Molecular Formula
C23H32N6O4S·HCl·3(H2O)
Targets
PDE1: 180 nM (IC50); PDE3: >1000 nM (IC50); PDE4: >1000 nM (IC50); PDE5: 0.7 nM (IC50)
Form
Lyophilized powder
Purity
≥98%
Titer
Free from inappropriate visible particulates, foreign matter, discoloration, or other defects
Applications
Vardenafil is a metabolism inhibitor that plays a key role in increasing blood flow to the penis, helping achieve and maintain an erection.
Publications
Publications (0)

Publications

×
Publications

Thank you for choosing our products for your research. By sharing your publications or experimental feedback, you provide invaluable insights that help fellow scientists accelerate their discoveries. Your contribution also drives our commitment to continuous product optimization.

As a token of our appreciation, verified submissions will receive an exclusive discount code for your next order.

*Submitted research data and images may be featured on our product pages. We strictly protect your personal privacy; no sensitive contact information will ever be disclosed.

  • You can upload up to 5 images or ZIP files, and the size of a single file may not exceed 5MB.
Related Products
Quick Links

About Us

CD BioGlyco is a world-class biotechnology company with offices in many countries. Our products and services provide a viable option to what is otherwise available.

Contact Us

Copyright © CD BioGlyco. All rights reserved.
0